Praxis Pauses Vormatrigine Study Amid Trial Setbacks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: stocktwits
- Study Pause: Praxis announced a pause in enrollment for the POWER2 study to reassess the vormatrigine program and consider potential modifications, while no immediate changes were reported for other ongoing trials or regulatory timelines, which may impact the company's future R&D direction.
- Trial Results Disappoint: In the POWER1 trial, vormatrigine failed to meet its primary endpoint of reducing monthly seizure frequency, although it showed a promising 50% responder rate in the higher dose group, indicating some efficacy that may not be sufficient to support its market outlook.
- Market Reaction: Praxis shares plunged nearly 12% in after-hours trading, reflecting investor disappointment over the failure of vormatrigine, while retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating confidence in the company's other drug candidates.
- Future Outlook: Despite the disappointing results for vormatrigine, Praxis remains on track for the commercial launch of relutrigine and ulixacaltamide, with the FDA expected to make decisions on these applications in the coming months, potentially providing new growth opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 349.970
Low
95.00
Averages
456.71
High
843.00
Current: 349.970
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is an integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company's product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-080, Elsunersen, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Praxis Pauses Vormatrigine Study Amid Trial Setbacks
- Study Pause: Praxis announced a pause in enrollment for the POWER2 study to reassess the vormatrigine program and consider potential modifications, while no immediate changes were reported for other ongoing trials or regulatory timelines, which may impact the company's future R&D direction.
- Trial Results Disappoint: In the POWER1 trial, vormatrigine failed to meet its primary endpoint of reducing monthly seizure frequency, although it showed a promising 50% responder rate in the higher dose group, indicating some efficacy that may not be sufficient to support its market outlook.
- Market Reaction: Praxis shares plunged nearly 12% in after-hours trading, reflecting investor disappointment over the failure of vormatrigine, while retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating confidence in the company's other drug candidates.
- Future Outlook: Despite the disappointing results for vormatrigine, Praxis remains on track for the commercial launch of relutrigine and ulixacaltamide, with the FDA expected to make decisions on these applications in the coming months, potentially providing new growth opportunities for the company.
See More
POWER1 Study Results Fail to Meet Primary Success Measure
- Study Results Analysis: The POWER1 study did not meet its primary success measure; however, a 50% response rate was achieved in the higher dose (30mg) group, indicating a more pronounced reduction in seizures during the latter half of the study, despite overall results falling short of expectations.
- Safety Assessment: Vormatrigine was generally well-tolerated, with adverse event-related discontinuations below 10%, suggesting a high safety profile that may enhance patient adherence to treatment.
- Patient Transition Status: Approximately 90% of patients from the vormatrigine arm transitioned to the open-label extension (OLE) study, indicating sustained interest and potential long-term efficacy of the drug among participants.
- Study Adjustment Plans: Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and consider potential modifications, reflecting the company's cautious approach to research direction and aiming to optimize future clinical development strategies.
See More
B Group Acquires Stake in Bright Minds Biosciences
- New Investment Position: B Group disclosed in its May 15, 2026 SEC filing that it acquired 67,500 shares of Bright Minds Biosciences for an estimated $5.43 million, indicating confidence in the company's future growth potential.
- Significant Stake: This acquisition represents approximately 4% of B Group's reportable AUM, reflecting its strategic positioning within the biotechnology sector.
- Strong Market Performance: Bright Minds' shares have surged nearly 175% over the past year, significantly outperforming the S&P 500's 25% increase, highlighting market confidence in its drug development prospects.
- Increased R&D Investment: Bright Minds ramped up its R&D spending to C$18.7 million in the first half of fiscal 2026, a substantial increase from C$3.6 million a year earlier, demonstrating accelerated efforts in developing its lead drug BMB-101 for drug-resistant epilepsy.
See More
HighVista Strategies Cuts Stake in Viridian Therapeutics by $7 Million
- Stake Reduction Details: HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics in its SEC filing dated May 15, 2026, representing an estimated $7.08 million trade, indicating a cautious outlook on the company's future performance.
- Impact of Stock Price Fluctuations: Despite Viridian Therapeutics' stock price rising 35% over the past year, the value of its position declined by $8.97 million at quarter-end, reflecting market concerns regarding the upcoming FDA decision.
- Company Financial Overview: Viridian's latest financial report indicates a revenue of $70.85 million and a net loss of $342.6 million over the trailing twelve months, highlighting the financial pressures faced during its development phase, which may affect investor confidence.
- Market Outlook and Challenges: With an FDA decision looming on June 30 for its lead therapy, Viridian's market performance may be impacted, especially after its Phase 3 clinical data fell short of expectations, prompting investors to carefully assess risks and opportunities.
See More
Praxis Precision Medicines FDA Accepts New Drug Application for Ulixacaltamide
- FDA Application Progress: Praxis Precision Medicines' new drug application for ulixacaltamide HCl has been accepted for review by the FDA, marking a significant advancement in addressing essential tremor, a common movement disorder affecting nearly 7 million Americans, which is expected to enhance the company's market competitiveness.
- Clinical Trial Success: The application is supported by data from the company's Essential3 Phase 3 clinical trials, where two pivotal studies met their primary endpoints, demonstrating statistically and clinically significant results for ulixacaltamide in adults with essential tremor, further strengthening its market outlook.
- Target Action Date: The FDA has set January 29, 2027, as the target action date for the new drug application and has not indicated plans for an advisory committee meeting, which could expedite the approval process and boost investor confidence.
- Positive Market Reaction: Praxis's stock rose approximately 6% in premarket trading, reflecting investor optimism regarding the FDA's acceptance of the application, signaling potential future growth for the company.
See More
Praxis Precision Medicines' NDA for Ulixacaltamide Accepted by FDA
- FDA Review Acceptance: Praxis Precision Medicines announced that its New Drug Application (NDA) for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, marking a significant advancement in the company's therapeutic pipeline.
- Key Timeline: The FDA has set a target action date of January 29, 2027, under the Prescription Drug User Fee Act (PDUFA), indicating that the company will face a critical regulatory review phase in its development plans over the coming years.
- Clinical Trial Support: The NDA submission is backed by positive results from the Essential3 Phase 3 clinical program, which included two concurrently enrolled pivotal studies demonstrating statistically and clinically significant efficacy, laying a solid foundation for the drug's market potential.
- Good Safety Profile: Ulixacaltamide was generally well tolerated in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events reported, enhancing the likelihood of FDA approval.
See More
Praxis Pauses Vormatrigine Study Amid Trial Setbacks
- Study Pause: Praxis announced a pause in enrollment for the POWER2 study to reassess the vormatrigine program and consider potential modifications, while no immediate changes were reported for other ongoing trials or regulatory timelines, which may impact the company's future R&D direction.
- Trial Results Disappoint: In the POWER1 trial, vormatrigine failed to meet its primary endpoint of reducing monthly seizure frequency, although it showed a promising 50% responder rate in the higher dose group, indicating some efficacy that may not be sufficient to support its market outlook.
- Market Reaction: Praxis shares plunged nearly 12% in after-hours trading, reflecting investor disappointment over the failure of vormatrigine, while retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating confidence in the company's other drug candidates.
- Future Outlook: Despite the disappointing results for vormatrigine, Praxis remains on track for the commercial launch of relutrigine and ulixacaltamide, with the FDA expected to make decisions on these applications in the coming months, potentially providing new growth opportunities for the company.
See More
POWER1 Study Results Fail to Meet Primary Success Measure
- Study Results Analysis: The POWER1 study did not meet its primary success measure; however, a 50% response rate was achieved in the higher dose (30mg) group, indicating a more pronounced reduction in seizures during the latter half of the study, despite overall results falling short of expectations.
- Safety Assessment: Vormatrigine was generally well-tolerated, with adverse event-related discontinuations below 10%, suggesting a high safety profile that may enhance patient adherence to treatment.
- Patient Transition Status: Approximately 90% of patients from the vormatrigine arm transitioned to the open-label extension (OLE) study, indicating sustained interest and potential long-term efficacy of the drug among participants.
- Study Adjustment Plans: Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and consider potential modifications, reflecting the company's cautious approach to research direction and aiming to optimize future clinical development strategies.
See More
B Group Acquires Stake in Bright Minds Biosciences
- New Investment Position: B Group disclosed in its May 15, 2026 SEC filing that it acquired 67,500 shares of Bright Minds Biosciences for an estimated $5.43 million, indicating confidence in the company's future growth potential.
- Significant Stake: This acquisition represents approximately 4% of B Group's reportable AUM, reflecting its strategic positioning within the biotechnology sector.
- Strong Market Performance: Bright Minds' shares have surged nearly 175% over the past year, significantly outperforming the S&P 500's 25% increase, highlighting market confidence in its drug development prospects.
- Increased R&D Investment: Bright Minds ramped up its R&D spending to C$18.7 million in the first half of fiscal 2026, a substantial increase from C$3.6 million a year earlier, demonstrating accelerated efforts in developing its lead drug BMB-101 for drug-resistant epilepsy.
See More
HighVista Strategies Cuts Stake in Viridian Therapeutics by $7 Million
- Stake Reduction Details: HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics in its SEC filing dated May 15, 2026, representing an estimated $7.08 million trade, indicating a cautious outlook on the company's future performance.
- Impact of Stock Price Fluctuations: Despite Viridian Therapeutics' stock price rising 35% over the past year, the value of its position declined by $8.97 million at quarter-end, reflecting market concerns regarding the upcoming FDA decision.
- Company Financial Overview: Viridian's latest financial report indicates a revenue of $70.85 million and a net loss of $342.6 million over the trailing twelve months, highlighting the financial pressures faced during its development phase, which may affect investor confidence.
- Market Outlook and Challenges: With an FDA decision looming on June 30 for its lead therapy, Viridian's market performance may be impacted, especially after its Phase 3 clinical data fell short of expectations, prompting investors to carefully assess risks and opportunities.
See More
Praxis Precision Medicines FDA Accepts New Drug Application for Ulixacaltamide
- FDA Application Progress: Praxis Precision Medicines' new drug application for ulixacaltamide HCl has been accepted for review by the FDA, marking a significant advancement in addressing essential tremor, a common movement disorder affecting nearly 7 million Americans, which is expected to enhance the company's market competitiveness.
- Clinical Trial Success: The application is supported by data from the company's Essential3 Phase 3 clinical trials, where two pivotal studies met their primary endpoints, demonstrating statistically and clinically significant results for ulixacaltamide in adults with essential tremor, further strengthening its market outlook.
- Target Action Date: The FDA has set January 29, 2027, as the target action date for the new drug application and has not indicated plans for an advisory committee meeting, which could expedite the approval process and boost investor confidence.
- Positive Market Reaction: Praxis's stock rose approximately 6% in premarket trading, reflecting investor optimism regarding the FDA's acceptance of the application, signaling potential future growth for the company.
See More
Praxis Precision Medicines' NDA for Ulixacaltamide Accepted by FDA
- FDA Review Acceptance: Praxis Precision Medicines announced that its New Drug Application (NDA) for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, marking a significant advancement in the company's therapeutic pipeline.
- Key Timeline: The FDA has set a target action date of January 29, 2027, under the Prescription Drug User Fee Act (PDUFA), indicating that the company will face a critical regulatory review phase in its development plans over the coming years.
- Clinical Trial Support: The NDA submission is backed by positive results from the Essential3 Phase 3 clinical program, which included two concurrently enrolled pivotal studies demonstrating statistically and clinically significant efficacy, laying a solid foundation for the drug's market potential.
- Good Safety Profile: Ulixacaltamide was generally well tolerated in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events reported, enhancing the likelihood of FDA approval.
See More
